PubRank

Regional correlations between [(11)C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27981028)

Published in Neuroimage Clin on November 11, 2016

Authors

Sang Won Seo1, Nagehan Ayakta2, Lea T Grinberg3, Sylvia Villeneuve4, Manja Lehmann5, Bruce Reed6, Charles DeCarli7, Bruce L Miller8, Howard J Rosen8, Adam L Boxer8, James P O'Neil9, Lee-Way Jin10, William W Seeley8, William J Jagust2, Gil D Rabinovici2

Author Affiliations

1: Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA; Helen Wills Neuroscience Institute, University of California, Berkeley, USA; Lawrence Berkeley National Laboratory, USA; Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea.
2: Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA; Helen Wills Neuroscience Institute, University of California, Berkeley, USA; Lawrence Berkeley National Laboratory, USA.
3: Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA; Department of Pathology, University of California, San Francisco, USA.
4: Helen Wills Neuroscience Institute, University of California, Berkeley, USA; Department of Psychiatry, McGill University, Montreal, Canada.
5: Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA; Dementia Research Centre, University College London, London, United Kingdom.
6: Center for Scientific Review, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, School of Medicine, University of California, Davis, USA.
7: Department of Neurology, School of Medicine, University of California, Davis, USA.
8: Memory and Aging Center, Department of Neurology, University of California, San Francisco, USA.
9: Lawrence Berkeley National Laboratory, USA.
10: Department of Pathology and Laboratory Medicine, University of California, Davis, USA.

Associated clinical trials:

Alzheimer Biomarkers on CSF of Elderly Patients Undergoing Surgery | NCT03977025

Articles cited by this ↗

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41

Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage (2002) 49.90

Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80

[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10

Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90

Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66

Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain (2007) 2.88

Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab (1992) 2.70

Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol (1989) 2.61

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61

Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol (1988) 2.42

The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci (2003) 2.06

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol (2015) 1.91

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86

Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol (2003) 1.82

Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64

11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology (2010) 1.43

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol (2011) 1.40

Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging (2010) 1.37

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31

In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29

Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol (1990) 1.23

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement (2015) 1.20

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain (2015) 1.14

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging (2012) 1.10

Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94

Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI. Eur J Nucl Med Mol Imaging (2013) 0.80